The FDA approval was based on results of three randomized, vehicle-controlled, 12-week studies and two 1-year studies with patients with moderate to severe eczema who were not refractory to other treatment. One of the 12-week studies included 351 patients 2-15 years of age, and the other ...
The FDA approval was based on results of three randomized, vehicle-controlled, 12-week studies and two 1-year studies with patients with moderate to severe eczema who were not refractory to other treatment. One of the 12-week studies included 351 patients 2-15 years of age, and the other ...
CardiospermumHalicacabum (Balloon Vine)is a climber that produces ornamental seed pods that resemble balloons. It has been examined that that each part of the plant, from its root to the seed has its own medicinal component for thetreatmentof different skin conditions such as eczema, psoriasis, a...
Three trials involving more than 2,100 adults with moderate to severe eczema found that dupilumab appeared to reduce itching and produce clearer skin after 16 weeks of treatment, according to the FDA. The participants in these trials were already using topical eczema medications. The most commonly ...
The findings suggest dupilumab is a safe, effective treatment for cases of erythrodermic atopic dermatitis, or eczema, in which more than 90% of the body was affected. Atopic dermatitis (AD) is the most common type ofeczema, affecting more than 9.6 million children and about 16.5 million adu...
designed for individuals who haven’t responded adequately to topical therapies, including pediatric patients weighing at least 88 pounds. The approval is supported by data from major studies, ADvocate 1, ADvocate 2, and Adhere, which have involved more than 1,000 patients with uncontrolled eczema....
A new class of medications, the JAK inhibitors, are recently approved for eczema and other indications. Opzeulra is indicated for short-term and non-continuous chronic treatment of mild to moderate eczema in non-immunocompromised adults and children 12 years of age and older whose disease is not...
(TCI) are still considered the main topical therapies in disease treatment. However, despite being very effective, TCS and TCI are not recommended for continuous long-term use, due to potential safety issues. Although research in AD has focused primarily on systemic drugs, more than 20 new ...
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), continues to challenge treatment paradigms. Advancements in therapeutic options have been have been driven by Phase 2 and 3 clinical trials of new drug classes, particularly sphingosine-1-phosphate (S1P...
Neonatal surgeryis the sub-specialty of pediatrics surgery which is dealing with all thesurgical operationsin newborn infants, especially theillorpremature newborn. It is responsible for the treatment of many disorders through surgical operations in newborn infants and playing vital role in saving liv...